Study of FKC289 for relapsed membranous nephropathy
Part of Kidney & urinary clinical trials.
This trial tests a new treatment called FKC289 for people whose membranous nephropathy (a kidney condition where the immune system attacks the kidney's filters) has come back or not improved with other treatments. The goal is to see if FKC289 is safe and can reduce protein in the urine, which indicates how well the kidney is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of primary membranous nephropathy from a kidney biopsy within the last 2 years.
- Your disease must have relapsed (come back) or not responded to prior treatment.
- A blood test must show a specific antibody (anti-PLA2R) above 50 units/mL.
- You must have a high amount of protein in your urine (more than 3.5 grams in 24 hours).
- You must not have an active infection or have had one within 2 weeks before the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This trial tests an investigational drug called YK012 for people with a kidney disease called primary membranous nephropathy. The study aims to see if YK012 is safe and helpful for those whose condition is very high risk and has not improved with standard treatments.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.